Caliway’s Fat Reduction Drug Candidate CBL-514 Completes U.S. FDA IND Submission for Phase 2 Clinical Study in Weight Management, Expanding Development Combined with GLP-1RA-Based Weight-Loss Therapies

The judge in the federal lawsuit brought by the Metropolitan Transportation Authority to protect congestion pricing tolls has scheduled two hours of oral arguments on Jan. 28.U.S. District Judge Lewis Liman, who is presiding over Metropolitan Transportation Authority v. Duffy,…

The NYPD’s Hate Crimes Task Force is investigating a criminal mischief incident in Kew Gardens involving the destruction of a menorah.

Police are searching for a man they say took thousands of dollars in merchandise from a cell phone store in Woodhaven this month. According to the NYPD, on Dec. 11, 2025, at approximately 5:15 p.m., police were notified of a…

Several long-awaited changes from the Metropolitan Transportation Authority, including a 10-cent-per-ride transit increase, will take effect Sunday, Jan. 4.The base fare for subways, local buses and Access-A-Ride will increase from $2.90 to $3. The reduced fare will increase from $1.45…

NASHVILLE, Tenn., Dec. 26, 2025 /PRNewswire/ — LLVision has served as the industry partner on an international research project that received the AIS Impact Award 2025. The award, announced at the ICIS 2025 Conference in Nashville, recognizes the use of…

– Secured a total of 55 million in R&D funding, including 40 million in upfront payment and 15 million in equity investment

Caliway has completed submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a Phase 2 clinical study of CBL-514 for weight management (CBL-0201WR Phase 2).The study will evaluate CBL-514 in combination with…

NEW YORK, Dec. 24, 2025 /PRNewswire/ —

NEW YORK, Dec. 24, 2025 /PRNewswire/ —

ANDOVER, Mass., Dec. 24, 2025 /PRNewswire/ — TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on December 22, 2025, TransMedics…

NEW YORK, Dec. 24, 2025 /PRNewswire/ — Further to its news release dated December 22, 2025, Scully Royalty Ltd. (the “Company”) (NYSE: SRL) announces that it has filed an appeal of the December 19, 2025 decision of the Grand Court…